ligelizumab ligelizumab ligelizumab (inn; development code qge031) is a humanized igg1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. it is an anti-ige that binds to ighe an acts as an immunomodulator. ligelizumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetigheclinical dataother namesqge031atc codenoneidentifierscas number1322627-61-1chemspidernoneuniil8le0l691tkeggd11761chemical and physical dataformulac6534h10000n1716o2038s44molar mass146612.49 g·mol−1 this drug was developed by novartis pharma ag. research funded by novartis pharma concluded that ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo.